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4Department of Medicine, Pennsylvania Hospital, 230 W Washington Square, Philadelphia, PA 19106 USA; 5Johnson & Johnson Pharmaceutical
Research and Development LLC, 1125 Trenton-Harbourton Road, PO Box 200, M/S K304, Titusville, New Jersey 08560 USA; 6Amgen Inc.,
Thousand Oaks, CA 91320 USA; 7First Department of Medicine, Center for Oncology and Haematology, Wilhelminenspital, Montleartstrasse 37,
Vienna A-1171, Austria
BACKGROUND: Cancer patients often develop the potentially debilitating condition of anaemia. Numerous controlled studies indicate
that erythropoiesis-stimulating agents (ESAs) can raise haemoglobin levels and reduce transfusion requirements in anaemic cancer
patients receiving chemotherapy. To evaluate recent safety concerns regarding ESAs, we carried out a meta-analysis of controlled
ESA oncology trials to examine whether ESA use affects survival, disease progression and risk of venous-thromboembolic events.
METHODS: This meta-analysis included studies from the 2006 Cochrane meta-analysis, studies published/updated since the 2006
Cochrane report, and unpublished trial data from Amgen and Centocor Ortho Biotech. The 60 studies analysed (15 323 patients)
were conducted in the settings of chemotherapy/radiochemotherapy, radiotherapy only treatment or anaemia of cancer. Data were
summarised using odds ratios (ORs) with 95% confidence intervals (CIs).
RESULTS: Results indicated that ESA use did not significantly affect mortality (60 studies: OR¼ 1.06; 95% CI: 0.97–1.15) or disease
progression (26 studies: OR¼ 1.01; 95% CI: 0.90–1.14), but increased the risk for venous-thromoboembolic events (44 studies:
OR¼ 1.48; 95% CI: 1.28–1.72).
CONCLUSION: Though this meta-analysis showed no significant effect of ESAs on survival or disease progression, prospectively
designed, future randomised clinical trials will further examine the safety and efficacy of ESAs when used according to the revised
labelling information.
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Cancer patients commonly develop anaemia due to either cancer
itself or to treatments such as myelosuppressive chemo-
therapy (Groopman and Itri, 1999; Knight et al, 2004; Ludwig
et al, 2004). During a large European survey of cancer patients
with different tumour types and treatments, 67% of 13 628
patients were anaemic (defined as haemoglobin level o12 g dl1
(7.5mmol l1)) at some time during the survey; anaemia was
reported in 75% of those patients who received chemotherapy
(Ludwig et al, 2004). Anaemia has been reported to be a potential
risk factor for increased mortality, decreased efficacy of cancer
treatments and longer hospitalisations (Schwartz, 2007; Spence,
2007). Anaemia can also increase fatigue, leading to reduced
physical functioning and reduced quality of life (Curt et al, 2000).
Although red blood cell (RBC) transfusions quickly correct
anaemia, the effect is transient and transfusions carry inherent
risks, including exposure to infectious agents (Barbara, 2004) and
transfusion-related acute lung injury (Looney et al, 2004). A recent
meta-analysis by the Cochrane Collaboration of randomised trials,
prospective cohorts and retrospective surveys has also revealed
that colorectal cancer patients receiving transfusions periopera-
tively have an increased risk for cancer recurrence (Amato and
Pescatori, 2006).
Erythropoiesis-stimulating agents (ESAs) include recombinant
erythropoietic glycoproteins developed as an anaemia-therapy
alternative to RBC transfusions and their associated risks. ESAs
approved in the United States of America (US) for treating chemo-
therapy-induced anaemia (CIA) in patients with non-myeloid
malignancies include Epoetin alfa (Ortho, 2009) and darbepoetin
alfa (Amgen, 2009). ESAs are also approved for this indication in
the European Union (EU) (EMEA, 2008; eMC, 2008). Many clinical
trials have demonstrated the efficacy and short-term safety of ESAs
for raising and maintaining haemoglobin concentrations and for
reducing RBC-transfusion rates (Glaspy et al, 1997; Demetri et al,
1998; Gabrilove et al, 2001; Littlewood et al, 2001; Vansteenkiste
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et al, 2002; Hedenus et al, 2003). Without using ESAs about
40–50% of CIA patients require transfusions (Littlewood et al,
2001; Vansteenkiste et al, 2002; Hedenus et al, 2003). That ESA
therapy can reduce fatigue symptoms and measurably improve
quality of life has been reported in several ESA trials (Vansteen-
kiste et al, 2002; Cella et al, 2003), meta-analyses of ESA studies
(Ross et al, 2006; Minton et al, 2008) and in evidence-based ESA
guidelines (Bokemeyer et al, 2007).
Though two trials suggested that ESA use might increase
survival (enhanced treatment effects due to increased tumour-cell
oxygenation was one postulated mechanism) (Littlewood et al,
2001; Vansteenkiste et al, 2002), several subsequent trials reported
that targeting a haemoglobin level ofX12 g dl1 in cancer patients
receiving chemotherapy resulted in greater mortality in the ESA
arm (Hedenus et al, 2003; Leyland-Jones et al, 2005; Amgen, 2007;
ODAC, 2008). An ESA-associated increase in mortality and/or
disease progression has also been reported in some controlled
studies conducted in cancer settings off-label for ESA use, such as
patients receiving radiotherapy only (Henke et al, 2003; Overgaard
et al, 2007) or patients with anaemia not receiving radiotherapy
or chemotherapy (i.e., anaemia of cancer (AoC)) (Wright et al,
2007; Smith et al, 2008). These safety signals have been the
subject of three meetings (in 2004, 2007 and 2008) between the
Oncologic Drugs Advisory Committee (ODAC) to the Food and
Drug Administration (FDA) and the two US companies that
distribute ESAs (Amgen and Centocor Ortho Biotech, Horsham,
PA, USA, which is a subsidiary of Johnson & Johnson) (ODAC,
2008). Information on these safety signals has been added to the
US and EU ESA-labelling information (EMEA, 2008; eMC, 2008;
Amgen, 2009; Ortho, 2009). However, as an ESA-associated
increase in mortality and disease progression has not been seen
in a large number of other controlled ESA studies (Vansteenkiste
et al, 2002; Blohmer et al, 2004; Machtay et al, 2007; Moebus et al,
2007; Pirker et al, 2008; Aapro et al, 2008a), those studies reporting
adverse safety signals must be considered within the total body of
evidence.
Meta-analysis is a well-established method to systematically
evaluate available evidence, estimate an overall-treatment effect
and explore sources of heterogeneity in reported findings (Egger
et al, 1997). Four large meta-analyses of ESA trials in both
approved and off-label oncology settings have recently been
conducted (Bohlius et al, 2006; Ross et al, 2006; Seidenfeld et al,
2006; Bennett et al, 2008b). In the 2006 Cochrane Collaborative
analysis (encompassing studies published or publicly available
from 1985 to April 2005 that were conducted in the settings of
chemotherapy only, radiotherapy with or without chemotherapy
and AoC), 42 placebo- or standard-of-care-controlled ESA
oncology trials were meta-analysed for survival (8167 patients)
(Bohlius et al, 2005, 2006). The pooled results indicated a
statistically non-significant numerical increase in mortality risk
associated with ESA use (the odds ratio (OR) was 1.08 with a 95%
confidence interval (CI) of 0.99–1.18 for ESA-treated patients vs
control patients). Similar findings were reported in a meta-analysis
by Ross et al (2006) and in the Seidenfeld et al (2006) meta-
analysis from the US Agency for Healthcare Research and Quality
(AHRQ) (Ross et al, 2006; Seidenfeld et al, 2006). Several smaller
meta-analyses have also reported that ESA use has a non-
significant effect on survival in cancer patients (Hedenus et al,
2005; Aapro et al, 2006, 2008b; Boogaerts et al, 2006). However, a
recent large meta-analysis by Bennett et al (2008b) of 13 611
patients in 51 phase 3, controlled ESA oncology trials conducted in
the chemotherapy, radiotherapy only and AoC settings indicated
that mortality was significantly higher in the ESA group (Hazard
ratio (HR)¼ 1.10; 95% CI: 1.01–1.20; P¼ 0.03) (Bennett et al,
2008b).
To comprehensively examine whether ESA use affects safety
outcomes in cancer patients, we conducted a meta-analysis that
included (1) studies included in the Cochrane 2006 meta-analysis,
(2) controlled ESA studies in oncology published after April 2005
(the cut-off date for the Bohlius et al 2006 Cochrane review) up to
March 2008 and (3) the most recent, updated ESA-trial data
provided by Amgen and Centocor Ortho Biotech for unpublished
and published trials (these data were not available for the recent
Bennett et al (2008b) meta-analysis mentioned above). A total of
60 studies with survival data were identified, including all 51
studies analysed in Bennett et al (2008b). As the efficacy of ESAs
for increasing haemoglobin levels and reducing transfusion
requirements is well-established (Bohlius et al, 2006), our meta-
analyses focused on the effect of ESA use on survival, disease
progression and risk of venous-thromboembolic events (VTEs).
PATIENTS AND METHODS
Search strategy
The 2006 Cochrane Collaborative report (specifically Analysis
05.05) (Bohlius et al, 2006) was used as the basis for the present,
updated meta-analysis. To identify studies published since the
2006 Cochrane report (i.e., from April 2005 to March 2008), we
carried out a literature search of the BIOSIS Previews, Current
Contents, EMBASE and Ovid MEDLINE databases using the
following Boolean search string – ‘erythropoiesis stimulating
proteins (including all synonymous terms)’ and ‘cancer (including
‘neoplasm’ and ‘malignancy’)’. A search was also carried out for
relevant abstracts and associated poster presentations delivered
from 1995 to 2007 at conferences for the American Society of
Clinical Oncology (ASCO), American Society of Hematology
(ASH), San Antonio Breast Cancer Symposium (SABCS) and the
European Society for Medical Oncology (ESMO). Studies were
selected if they were randomised, controlled trials of cancer
patients treated with an ESA (Epoetin alfa, epoetin beta or
darbepoetin alfa) plus transfusions compared with control patients
who either received placebo or best standard of care for prophylaxis
or treatment of anaemia (e.g., transfusions without ESAs). Studies
had to report on death or percentage of death in each treatment
group or to have collected mortality data that were available for
analysis. Interim analyses of ESA trials were included, as well as ESA
studies that examined iron use in cancer patients. One study
(Blohmer et al, 2004) was rejected from the 2006 Cochrane analysis
because oral iron was used in the ESA group and not the control
group. This study was included in our analysis as it reported
survival data, no evidence exists to suggest that oral iron
supplementation affects mortality, and many ESA studies recom-
mend iron supplementation to maintain adequate iron availability
for erythropoiesis (Auerbach et al, 2004; Bastit et al, 2008).
We excluded those publications that were not written in English,
that were editorials, letters, clinical guidelines or case studies, and
that allowed ESAs to be administered to the control arm as part of
standard medical care. If two publications existed describing the
same study (e.g., an abstract and a manuscript), the most recent
publication was used. For studies conducted by Amgen and
Centocor Ortho Biotech, current data available from internal
databases for those randomised, controlled ESA trials that met the
search criteria used in the literature search were included in the
analyses. Database results did not always match previously
published results because longer-term follow-up data became
available or because interim data were updated with either more
recent interim data or the final data. In addition, death, disease
progression and incidence of VTEs were frequently described as
safety endpoints in the published literature and therefore,
published studies usually analysed patients by treatment received.
In this study-level meta-analysis, analyses used an intention-to-
treat or modified-intention-to-treat approach (patients who
received study drug were analysed). If data were not available by
randomised-treatment assignment, only then were the published
results used. Data for epoetin beta studies were collected from
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publications only and were not supplemented from internal
databases at Hoffmann-La Roche (Basel, Switzerland).
Three modifications were made to the 2006 Cochrane analytical
approach (Bohlius et al, 2006). First, our analysis collapsed
chemotherapy groups used in the 2006 Cochrane meta-analysis to
a single group, as ESA-labelling information does not differentiate
between chemotherapy regimens with and without platinum and
because the 2006 Cochrane mortality results were not significantly
different between chemotherapy groups. Second, trials in which a
majority of patients received chemotherapy (with or without
radiotherapy) were classified as chemotherapy studies; in the 2006
Cochrane analysis, studies in which patients received radiotherapy
and chemotherapy were classified as radiotherapy studies. Of note,
one study labelled as a radiotherapy study in the 2006 Cochrane
analysis (Wright et al, 2007) excluded patients who were to receive
curative radiation. This study was classified as an AoC study in the
present meta-analysis. Third, unlike the Cochrane analysis, we
excluded studies in patients with myelodysplastic syndromes
(MDS), as ESAs are not approved for use in MDS, which is a
separate disease from cancer. One study included in the Cochrane
2006 report as an AoC study (Thompson et al, 2000) was excluded
from the present meta-analysis because it was an MDS study.
Studies identified from the above literature search that also
reported data on the relationship between ESA use and disease
progression or VTE risk were meta-analysed to examine these
relationships. Additional literature searches did not identify any
additional controlled, ESA oncology studies reporting data on ESA
use and disease progression or VTE risk.
Statistical analyses
Data were summarised using ORs generated using the Compre-
hensive Meta-Analysis (V2) software. In contrast, the 2006
Cochrane Collaboration approach (Bohlius et al, 2006) reported
either an OR or HR. As the method by which an OR is calculated
provides a point estimate farther from unity (i.e., an estimate
further from the null) than that provided by an HR, an OR is a
more conservative estimate and may be more likely to detect a
safety signal. Data are presented as a forest plot of all studies with
an estimated OR and 95% CI. A random-effects model was used
because it assumes treatment effects are not identical in all studies.
Some analyses also used a fixed-effects model, which assumes that
the treatment effect is the same in each study and that differences
in results are due only to chance. Heterogeneity among studies was
quantified using the I2 inconsistency statistic, which is a measure
of inter-study variability as a proportion of total variability. When
inter-study variability is low, the fixed-effects and random-effects
models will yield very similar results.
For the present meta-analyses, both 1-year and long-term
follow-up survival data were available from the Breast Cancer
Erythropoietin Survival Trial (BEST study) (Leyland-Jones et al,
2005; Centocor Ortho Biotech, data on file). The 1-year BEST data
were used in the figures. For completeness, results using the BEST
long-term follow-up data are also provided within the text. The
long-term data from BEST were collected after the end of the
1-year randomised period. For chemotherapy studies, an influence
plot was generated that shows the estimated OR for mortality if an
individual chemotherapy study (such as BEST) was excluded from
the analysis.
As we did not have patient-level data for many of the studies
included in this study-level meta-analysis, an overall-mortality HR
was not calculated. However, sensitivity analyses were carried out
on 20 chemotherapy studies with long-term follow-up (46
months) to address concerns regarding the use of OR as a point
estimate in a meta-analysis. Patient-level data from 16 of the 20
studies were obtained from Amgen and Centocor Ortho Biotech. In
all, 4 of the 20 chemotherapy studies could not be included in the
patient-level analysis as primary data were not available (Oster-
borg et al, 2005; Engert, 2007; Strauss et al, 2008; Aapro et al,
2008a). However, the published manuscripts for Aapro et al
(2008a) and Osterborg et al (2005) provided HRs for survival.
Thus, sensitivity analyses were also carried using the published
HRs for these two studies. Data were combined and HRs for
mortality were calculated for each study and across all studies
combined (with study as a stratification factor) using an
unadjusted Cox’s proportional hazards model.
RESULTS
Study selection
The literature search for controlled, ESA oncology trials that
reported mortality or survival data identified 60 studies. In all, 19
were additional ESA studies that were added to 41 studies
identified from the 2006 Cochrane meta-analysis of survival in
ESA oncology trials (Bohlius et al, 2006) (Table 1). Of note, of the
Table 1 Characteristics of the 60 studies examined in the present meta-analysis
Study publication Study number or alias Treatment setting Tumour type
Number of
patients analysed
Studies not present in Cochrane 2006
aAapro et al, 2008a BRAVE Chemotherapy Breast 463
a,bBlohmer et al, 2004 AGO/NOGG
EPO-GER-8
Chemotherapy Cervical 250
Charu et al, 2007 AMG 20000219 AoC Non-myeloid 285
a,bDebus et al, 2006 EPO-GER-22 Chemotherapy NSCLC 385
Engert, 2007 HD-15 Chemotherapy Hodgkin’s lymphoma 688
Gordon et al, 2006 AMG 20030204 AoC Non-myeloid 218
aMilroy et al, 2003 EPO-INT-49 Chemotherapy NSCLC 424
Moebus et al, 2007 EPO-GER-7 Chemotherapy Breast 643
Mystakidou et al, 2005 N/A AoC Solid tumour 100
Overgaard et al, 2007 SE-2002-9001
(DAHANCA-10)
Radiotherapy Head and neck 515
aPirker et al, 2008 AMG 20010145 Chemotherapy SCLC 596
Pronzato et al, 2002 EPO-INT-47 Chemotherapy Breast 223
aSmith et al, 2008 AMG 20010103 AoC Non-myeloid 985
bStrauss et al, 2008 MARCH Chemotherapy Cervical 74
Taylor et al, 2005 AMG 20030232 Chemotherapy Non-myeloid 386
Wilkinson et al, 2006 EPO-INT-45 Chemotherapy Ovarian 181
aUnpublished PREPARE Chemotherapy Breast 733
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42 studies included in the 2006 Cochrane survival analysis, 1 study
was excluded from the present analysis as it was conducted in MDS
patients (Thompson et al, 2000). Of the 19 additional studies, 12
were in the chemotherapy setting, 1 was in the radiotherapy alone
setting and 6 were in AoC; for some of the 19 studies, updated,
unpublished data from Amgen and Centocor Ortho Biotech were
included in the present meta-analysis. Of the 41 studies selected
from the Cochrane 2006 report, 14 were identified as having
updated data available (e.g., results previously published in
abstracts were now available as final publications or updated data
were available from Amgen or Centocor Ortho Biotech) (Table 1).
In this literature review, the 60 identified studies were conducted
in patients with solid tumours and/or haematological malignancies
who received an ESA (Epoetin alfa, epoetin beta or darbepoetin
alfa) or control treatment (placebo or best standard of care). Only
one study was conducted in paediatric patients (Razzouk et al,
2006). Of the 60 studies, 26 reported disease progression outcomes
and 44 reported on the incidence of VTEs.
Mortality
Mortality was assessed in 60 randomised, controlled trials (41 from
the 2006 Cochrane analysis plus 19 additional studies) involving
15 323 patients (Figure 1). A total of 9 studies were in the AoC
Table 1 (Continued )
Study publication Study number or alias Treatment setting Tumour type
Number of
patients analysed
Unpublished EPO-CAN-203 AoC N/A 17c
Unpublished EPO-CAN-303 AoC N/A 16c
Studies included in Cochrane 2006 that had updates since Cochrane 2006
Chang et al, 2005 EPO-CAN-17 Chemotherapy Breast 354
bGoss et al, 2005 EPO-CAN-15 Chemotherapy SCLC 104
aGrote et al, 2005 N93-004 Chemotherapy SCLC 224
aHedenus et al, 2003 AMG 20000161 Chemotherapy Haematological 344
aLeyland-Jones et al, 2005 EPO-INT-76
(BEST)
Chemotherapy Breast 939
aMachtay et al, 2007 RTOG-99-03
PR99-03-046
Radiotherapy Head and neck 148
Razzouk et al, 2006 CR002296 Chemotherapy Solid or various haematological 224
Savonije et al, 2005 EPO-NED-17 Chemotherapy Solid tumours 315
a,bThomas et al, 2008 GOG-0191 Chemotherapy Cervical 114
aVansteenkiste et al, 2002 AMG 980297 Chemotherapy SCLC and NSCLC 314
aWright et al, 2007 EPO-CAN-20 AoC NSCLC 70
Unpublished EPO-INT-1 Chemotherapy Ovarian 246
Unpublished EPO-INT-3 Chemotherapy Solid or various haematological 201
aUnpublished EPO-GBR-7 Radiotherapy Head and neck 300
Studies included in Cochrane 2006 that have had no updates
Abels, 1993 N/A AoC Mixed 124
Bamias et al, 2003 N/A Chemotherapy Solid tumour 144
Cascinu et al, 1994 N/A Chemotherapy Mixed 100
Case et al, 1993 N/A Chemotherapy Mixed 157
Cazzola et al, 1995 MF4313 Chemotherapy Multiple myeloma or
non-Hodgkin’s lymphoma
146
Coiffier et al, 2001 MF4421 Chemotherapy Mixed 262
Dammacco et al, 2001 EPO-INT-2 Chemotherapy Multiple myeloma 145
Del Mastro et al, 1997 N/A Chemotherapy Breast 62
Dunphy et al, 1999 N/A Chemotherapy Head and neck or lung carcinoma 30
Hedenus et al, 2002 AMG 990114 Chemotherapy Lymphoproliferative 66
Henke et al, 2003 ENHANCE Radiotherapy Head and neck 351
Henry et al, 1995 N/A Chemotherapy Mixed 132
Kotasek et al, 2003 AMG 980291 Chemotherapy Solid tumours 249
Kurz et al, 1997 N/A Chemotherapy Gynaecological 35
aLittlewood et al, 2001 EPO-INT-10 Chemotherapy Solid or non-myeloid malignancy 375
Oberhoff et al, 1998 N/A Chemotherapy Solid tumours 218
O’Shaughnessy et al, 2005 PR00-27-005 Chemotherapy Breast 100
Osterborg et al, 1996 MF4250 Chemotherapy Haematological 144
aOsterborg et al, 2005 MF4467 Chemotherapy Haematological 343
Pangalis et al, 1995 P-174 Chemotherapy B-chronic lymphocytic leukaemia 45
Rose et al, 1994 J89-040 Chemotherapy Chronic lymphocytic leukaemia 221
Smith et al, 2003 AMG 990111 AoC Mixed 86 (Q3W/Q4W)
ten Bokkel Huinink et al, 1998 N/A Chemotherapy Ovarian 120
Thatcher et al, 1999 CC2574-P-169 Chemotherapy SCLC 130
bThrouvalas et al, 2000 N/A Chemotherapy Cervix or bladder 55
bVadhan-Raj et al, 2004 PR00-03-006 Chemotherapy Gastric and rectal 60
Witzig et al, 2005 PR98-27-008 Chemotherapy Mixed 344
Abbreviations: AoC¼ anaemia of cancer; N/A¼ not available; NSCLC¼ non-small-cell lung cancer; SCLC¼ small-cell lung cancer; Q3W¼ every 3 weeks; Q4W¼ every
4 weeks. aThese studies have reported a mortality hazard ratio that is publicly available in a journal or abstract publication, the ODAC (2008) briefing book or in Hedenus et al
(2005). bPatients received chemotherapy and radiotherapy. cThe planned enrolment was 160 patients for EPO-CAN-203 and 540 patients for EPO-CAN 303. Both studies
were stopped early because of poor accrual (Centocor Ortho Biotech, data on file).
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Treatment type Study name
Odds Lower Upper
ratio limit limit
AoC Mystakidou 2005
Gordon 2006
Abels 1993
Smith 2008
EPO-CAN-203
Charu 2007
EPO-CAN-303
Smith 2003
Wright 2007
Random effects model: AOC
Radiotherapy Only EPO-GBR-7
Machtay 2007
Overgaard 2007
Henke 2003
Chemotherapy Dammacco 2001 0.27 0.07 1.01
* Throuvalas 2000 0.31 0.01 7.95
Del Mastro 1997 0.31 0.03 3.17
Dunphy 1999 0.31 0.01 8.28
* Vadhan-Raj 2004 0.34 0.01 8.80
Oberhoff 1998 0.35 0.12 1.04
Cazzola 1995 0.49 0.04 5.56
* Debus 2006 0.58 0.35 0.96
EPO-INT-3 0.61 0.26 1.41
Vansteenkiste 2002 0.62 0.38 1.01
Henry 1995 0.69 0.34 1.40
* Blohmer 2004 0.73 0.37 1.44
Ten Bokkel 1998 0.75 0.13 4.28
Pirker 2008 0.79 0.52 1.21
Littlewood 2001 0.81 0.52 1.28
Kotasek 2003 0.83 0.33 2.05
0.84 0.45 1.59
0.89 0.15 5.36
* Goss 2005 0.93 0.43 2.00
Coiffer 2001 0.97 0.35 2.66
Chang 2005 0.97 0.55 1.73
Witzig 2005 0.98 0.62 1.55
Razzouk 2006 1.00 0.14 7.23
Aapro 2008a 1.02 0.67 1.53
Moebus 2007 1.05 0.70 1.57
Osterborg 2005 1.08 0.69 1.67
Osterborg 1996 1.10 0.50 2.44
Milroy 2003 1.16 0.79 1.72
Savonije 2005 1.18 0.73 1.90
* Thomas 2008 1.19 0.55 2.56
Engert 2007 1.21 0.32 4.55
Thatcher 1999 1.21 0.30 4.93
Case 1993 1.22 0.65 2.30
Pronzato 2002 1.23 0.63 2.39
Rose 1994 1.39 0.64 2.98
PREPARE 1.40 0.90 2.15
Leyland-Jones 2005 1.42 1.07 1.90
Hedenus 2003 1.48 0.97 2.27
Grote 2005 1.54 0.64 3.72
Bamias 2003 1.83 0.51 6.55
EPO-INT-1 1.86 0.50 6.85
* Strauss 2008 2.15 0.63 7.35
O'Shaughnessy 2005 2.94 0.12 73.93
Wilkinson 2006 3.57 0.18 70.31
1.03 0.93 1.13
1.06 0.97 1.15
0.1 0.2 0.5 1 2 5 10
Random effects model: radiotherapy only
Random effects model: overall
Random effects model: chemotherapy
95% CI 
0.49 0.04 5.58
0.69 0.25 1.91
0.74 0.36 1.49
1.14 0.89 1.47
1.40 0.05 36.45
1.56 0.52 4.69
2.05 0.07 58.65
2.56 0.13 51.56
2.82 0.28 28.56
1.09 0.87 1.36
0.95 0.60 1.49
1.01 0.53 1.93
1.25 0.88 1.78
1.41 0.93 2.16
1.18 0.95 1.47
All cancer patients
60 studies (15323 pts)
OR = 1.06 (95% CI: 0.97–1.15)
Radiotherapy only
4 studies (1314 pts)
OR = 1.18 (95% CI: 0.95–1.47)
Chemotherapy
47 studies (12108 pts)
OR = 1.03 (95% CI: 0.93–1.13)
Anaemia of cancer
9 studies (1901 pts)
OR = 1.09 (95% CI: 0.87–1.36)
Two Studies of concern
Henke 2003 (ENHANCE)
Overgaard 2007 (DAHANCA-10)
Four Studies of concern
Thomas 2008 (GOG-0191)
Hedenus 2003 (AMG 20000161)
Leyland-Jones 2005 (BEST)
Amgen 2007 (PREPARE)
Two Studies of concern
Wright 2007 (EPO-CAN-20)
Smith 2008 (AMG 20010103)
Chemotherapy
with long-term follow-up
20 studies (8145 pts)
OR = 1.05 (95% CI: 0.92–1.19)
Taylor 2005
Pangalis1995 
Favours controlFavours ESA
A
B
Figure 1 Continued.
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Dammacco 2001 1.03 0.94 1.14
Throuvalas 2000 1.03 0.93 1.13
Del Mastro 1997 1.03 0.93 1.13
Dunphy 1999 1.03 0.93 1.13
Vadhan-Raj 2004 1.03 0.93 1.13
Oberhoff 1998 1.04 0.94 1.14
Cazzola 1995 1.03 0.93 1.13
Debus 2006 1.05 0.95 1.16
EPO-INT-3 1.03 0.94 1.14
Vansteenkiste 2002 1.05 0.95 1.16
Henry 1995 1.04 0.94 1.14
Blohmer 2004 1.03 0.94 1.14
Ten Bokkel 1998 1.03 0.93 1.13
Pirker 2008 1.04 0.94 1.15
Littlewood 2001 1.04 0.94 1.15
Kotasek 2003 1.03 0.93 1.14
Taylor 2005 1.03 0.94 1.14
Pangalis 1995 1.03 0.93 1.13
Goss 2005 1.03 0.93 1.13
Coiffer 2001 1.03 0.93 1.13
Chang 2005 1.03 0.93 1.14
Witzig 2005 1.03 0.93 1.14
Razzouk 2006 1.03 0.93 1.13
Aapro 2008a 1.03 0.93 1.14
Moebus 2007 1.03 0.93 1.13
Osterborg 2005 1.02 0.93 1.13
Osterborg 1996 1.03 0.93 1.13
Milroy 2003 1.02 0.92 1.13
Savonije 2005 1.02 0.93 1.13
Thomas 2008 1.02 0.93 1.13
Engert 2007 1.03 0.93 1.13
Thatcher 1999 1.03 0.93 1.13
Case 1993 1.02 0.93 1.13
Pronzato 2002 1.02 0.93 1.13
Rose 1994 1.02 0.93 1.13
PREPARE 1.01 0.92 1.12
Leyland-Jones 2005 0.98 0.89 1.09
Hedenus 2003 1.01 0.91 1.11
Grote 2005 1.02 0.93 1.13
Bamias 2003 1.02 0.93 1.13
EPO-INT-1 1.02 0.93 1.13
Strauss 2008 1.02 0.93 1.13
O'Shaughnessy 2005 1.03 0.93 1.13
Wilkinson 2006 1.03 0.93 1.13
1.03 0.93 1.13
0.5 1 2
Favours ESA Favours control
Name of
removed study
Odds ratio and 95% CI with each study removed
Odds
ratio
Lower
limit
Upper
limit
Random effects model: overall
Study name
95% CI
Odds Lower Upper
ratio limit limit
* Debus 2006 0.58 0.35 0.96
Vansteenkiste 2002 0.62 0.38 1.01
* Blohmer 2004 0.73 0.37 1.44
Pirker 2008 0.79 0.52 1.21
Littlewood 2001 0.81 0.52 1.28
Chang 2005 0.97 0.55 1.73
Witzig 2005 0.98 0.62 1.55
Aapro 2008a 1.02 0.67 1.53
Moebus 2007 1.05 0.70 1.57
Osterborg 2005 1.08 0.69 1.67
Milroy 2003 1.16 0.79 1.72
Savonije 2005 1.18 0.73 1.90
* Thomas 2008 1.19 0.55 2.56
Engert 2007 1.21 0.32 4.55
Pronzato 2002 1.23 0.63 2.39
PREPARE 1.40 0.90 2.15
Leyland-Jones 2005 1.42 1.07 1.90
Hedenus 2003 1.48 0.97 2.27
Grote 2005 1.54 0.64 3.72
* Strauss 2008 2.15 0.63 7.35
1.05 0.92 1.19
0.2 0.5 1 2 5 10
Favours ESA Favours control
Random effects model
C
D
Figure 1 Effect of erythropoiesis-stimulating agent (ESA) use on mortality. (A) Flow diagram of studies analysed. The odds ratio (OR) (95% confidence interval
(CI)) for the mortality of all 60 studies and for each cancer setting is given. Pts indicates patients. (B) Meta-analysis of mortality using 60 controlled studies carried
out in the settings of chemotherapy, anaemia of cancer (AoC) or radiotherapy only. This analysis included 15323 patients, with 8343 ESA-treated patients and
6980 control patients. An asterisk denotes radiochemotherapy studies. Three chemotherapy studies are not listed, as they reported no deaths in the ESA or
control arms. (C) Influence of each chemotherapy study on the mortality OR for all chemotherapy studies. This analysis calculated the mortality OR for the
chemotherapy studies combined after excluding each listed chemotherapy study. Of the 47 chemotherapy studies identified, 3 were not listed in the plot as they
reported no deaths in the ESA or control arms. (D) Study-level meta-analyses of mortality in 20 chemotherapy studies with long-term follow-up. This analysis
included 8145 patients, with 4183 ESA-treated patients and 3962 control patients. An asterisk denotes radiochemotherapy studies.
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setting, 4 in the radiotherapy only setting and 47 in the
chemotherapy setting. Of note, 3 of the 47 chemotherapy studies
reported no deaths in either treatment arm (Cascinu et al, 1994;
Kurz et al, 1997; Hedenus et al, 2002) and, thus, only 44
chemotherapy studies are listed in the plot shown in Figure 1B.
Long-term follow-up (46 months after the randomised study
period) was reported in 26 studies (20 were chemotherapy studies),
whereas the remaining 34 studies evaluated deaths on study.
Meta-analysis of all 60 studies based on a random-effects model
yielded an OR for mortality of 1.06 (95% CI: 0.97–1.15; results
were the same when a fixed-effects model was used) (Figure 1A
and B; Table 2). There was little heterogeneity among the trials
(I2¼ 0%). This analysis included the 1-year survival data from the
BEST study, which indicated higher mortality with ESA use in
breast cancer patients (Leyland-Jones et al, 2005). However, this
mortality signal has not been observed in long-term follow-up
BEST data (ODAC, 2008). If long-term follow-up BEST data (i.e.,
survival data collected beyond the 1-year treatment period) were
included (Leyland-Jones et al, 2005; ODAC, 2008), the mortality
OR was 1.02 (95% CI: 0.94–1.11; I2¼ 0%) using either the random-
effects or fixed-effects model.
Meta-analysis of the 47 chemotherapy studies (12 108 patients)
with either the random- or fixed-effects model resulted in an OR
for mortality of 1.03 (95% CI: 0.93–1.13; I2¼ 1.2%) (Figure 1A and B;
Table 2). The BEST study provided the greatest weight (11.4%) in
this analysis. The influence plot (Figure 1C) shows the effect of
removing the BEST study (with 1-year data) from the meta-
analysis of the chemotherapy studies; only removal of the BEST
study shifted the mortality OR to o1. Meta-analysis of the 47
chemotherapy studies with the long-term follow-up BEST data
resulted in a mortality OR of 0.98 (95% CI: 0.89–1.08) using
either a random- or fixed-effects model. Meta-analyses of mortality
in the off-label uses of AoC (9 studies; 1901 patients) and
radiotherapy only (4 studies; 1314 patients) yielded an OR higher
than that observed for the chemotherapy studies (Figure 1A and B;
Table 2).
Studies in the chemotherapy setting that reported a mean-
baseline haemoglobin concentration were analysed stratified by
the baseline haemoglobin concentration at study entry. This
analysis (Table 2) indicated a non-significant effect of ESAs on
mortality in studies with a reported mean-baseline haemoglobin
concentration of o10 g dl1 or 10–12 g dl1.
When mortality in the 20 chemotherapy studies with long-term
follow-up data (8145 patients) was analysed, the mortality OR was
1.05 (95% CI: 0.92–1.19; I2¼ 25.1%) using a random-effects model
(Figure 1A and D) and 1.06 (95% CI: 0.96–1.18) using a fixed-effects
model. If BEST long-term follow-up data were included (Leyland-
Jones et al, 2005; ODAC, 2008), the mortality OR was 1.00 (95% CI:
0.89–1.12; I2¼ 10.4%) using a random-effects model or 1.00 (95%
CI: 0.90–1.11) using a fixed-effects model. Sensitivity analyses of the
20 chemotherapy trials with long-term follow-up survival data
examined if OR estimates are effective for examining survival in
meta-analyses. Study-level ORs and both study-level and patient-
level HRs were estimated for mortality. Primary patient-level data
(obtained from Amgen and Centocor Ortho Biotech) and data from
the published literature were used. Though there are small variations,
the estimates summarizing the mortality results across studies
appeared to be consistent in indicating a small and non-significant
effect of ESA use on mortality in the chemotherapy setting (Table 3).
Disease progression
Of the 60 controlled ESA trials that measured survival, 26 included
a measure of disease progression (21 chemotherapy studies, 1 AoC
study and 4 radiotherapy only studies) (Figure 2A). The disease-
progression outcomes used (e.g., progression-free survival,
relapse-free survival, local-regional relapse, tumour response or
disease progression) and the quality of the tumour assessments
Table 2 Risk of death in patients receiving ESAs compared with patients not receiving ESAs: results from five meta-analyses
Number of trials Number of patients Statistic 95% Confidence interval
Current meta-analysis, All studies 60 15 323 1.06 OR 0.97–1.15
Chemotherapy studies 47 12 108 1.03 OR 0.93–1.13
Mean entry haemoglobin o10 g 100ml1 16 3265 0.99 OR 0.80–1.22
Mean entry haemoglobin 10–12 g 100ml1 13 3661 0.91 OR 0.77–1.08
Mean entry haemoglobin 412 g 100ml1 13 4522 1.13 OR 0.94–1.36
AoC studies 9 1901 1.09 OR 0.87–1.36
Radiotherapy studies 4 1314 1.18 OR 0.95–1.47
Cochrane (Bohlius et al, 2006), All studies 42 8167 1.08 OR 0.99–1.18
All studies, entry haemoglobin o10 g 100ml1 20 3765 1.01 OR 0.89–1.15
All studies, entry haemoglobin 10–o12 g 100ml1 8 1712 0.98 OR 0.82–1.16
All studies, entry haemoglobin 412 g 100ml1 7 1696 1.27 OR 1.05–1.54
Chemotherapy studiesa 30 6282 1.02 OR 0.90–1.15
AoC studies 3 276 1.14 OR 0.56–2.31
Radiotherapy studies 8 1187 1.27 OR 1.05–1.55
AHRQ (Seidenfeld et al, 2006), All studies 39 7891 1.08 Peto OR 0.98–1.18
All studies, entry haemoglobin o10 g 100ml1 17 3489 1.01 Peto OR 0.89–1.15
All studies, entry haemoglobin 10–12 g 100ml1 8 1712 0.98 Peto OR 0.82–1.16
All studies, entry haemoglobin 412 g 100ml1 7 1696 1.27 Peto OR 1.05–1.54
(Ross et al, 2006), All studies 17 2895 1.14 OR 0.90–1.45
CIA studies (entry haemoglobin o11 g 100ml1) 11 2014 0.99 OR 0.72–1.36
Non-CIA studies 6 881 1.39 OR 0.96–2.00
(Bennett et al, 2008b), All studies 51 13 611 1.10 HR 1.01–1.20
Chemotherapy or radiotherapy studies 45 11 522 1.09 HR 0.99–1.19
AoC studies 6 1800 1.29 HR 1.00–1.67
Abbreviations: All studies¼ all studies analysed from settings of chemotherapy, anaemia of cancer and radiotherapy only; AoC¼ anaemia of cancer; CIA¼ chemotherapy-
induced anaemia; ESA¼ erythropoiesis-stimulating agent; HR¼ hazard ratio; OR¼ odds ratio. aEstimated by Amgen based on original classification of studies from the Cochrane
2006
meta-analysis (Bohlius et al, 2006).
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employed varied. Only one study (AMG 20010145) (Pirker et al,
2008) rigorously assessed tumour progression radiographically
using blinded centralised review. This small-cell lung cancer study
in which all patients received the same chemotherapy regimen,
reported that ESAs had no significant effect on disease progression
(Pirker et al, 2008). In the remaining 25 studies, tumour
progression was evaluated by the investigator (23 studies), by
histopathology of tumour response (Amgen, 2007) or by radio-
graphic assessment without central review (Grote et al, 2005).
To examine the effect of ESA use on disease progression in these
26 studies (9646 patients) and to standardise the variable outcome
measures used to evaluate disease progression, ORs (ESA vs
control) were calculated for each study (Figure 2B). Only the
random-effects model was used since the many different disease
progression estimates used in these studies would be expected to
contribute to variability in the results. In the present meta-analysis,
results indicated that ESA use was associated with a non-significant
effect on disease progression (overall OR¼ 1.01; 95% CI: 0.90–1.14;
I2¼ 29.4%) (Figure 2B). When the 21 chemotherapy studies (7908
patients with 4053 ESA-treated patients and 3855 control patients)
that evaluated disease progression were meta-analysed, the result
also indicated a non-significant effect of ESA use on disease
progression (OR¼ 0.95; 95% CI: 0.85–1.06; I2¼ 2.3%).
VTE risk
An increased risk for VTEs with ESA use has been observed in
individual, randomised controlled ESA studies and is consistently
reported in the meta-analyses of ESA oncology trials (Table 4). The
current meta-analysis examined 44 studies (13 196 patients) that
reported the incidence of VTEs in the settings of chemotherapy (35
studies), AoC (6 studies) and radiotherapy only (3 studies). Results
revealed that the risk of VTEs was increased in ESA-treated
patients (OR¼ 1.48; 95% CI: 1.28–1.72; I2¼ 0%; results were the
same using either a random- or fixed-effects model) (Figure 3;
Table 4). A similar result was seen when the 35 chemotherapy
studies were analysed (OR¼ 1.48; 95% CI: 1.27–1.72; I2¼ 0%). A
meta-analysis for VTE risk carried out in the 18 chemotherapy
studies with long-term follow-up (6498 patients with 3859 ESA-
treated patients and 2639 control patients; these studies were
analysed as their reported VTE definitions were the most
consistent) also indicated an increased VTE risk with ESA use
(OR¼ 1.47; 95% CI: 1.24–1.74; I2¼ 0%; results were the same
using either a random- or fixed-effects model).
DISCUSSION
The present meta-analysis of studies in the chemotherapy,
radiotherapy and AoC oncology settings indicates that ESA use
is associated with a significant increase in VTE risk (44 studies
examined), but does not demonstrate a significant effect on
mortality (60 studies examined) or on disease progression (26
studies examined). However, the US and EU ESA-labelling
information describes how increased mortality and/or disease
progression has been observed in 8 individual studies included
in this meta-analysis: 4 in the chemotherapy setting (Hedenus
et al, 2003; Leyland-Jones et al, 2005; Amgen, 2007; Thomas et al,
2008), 2 in the radiotherapy setting (Henke et al, 2003; Overgaard
et al, 2007) and 2 in the AoC setting (Wright et al, 2007;
Smith et al, 2008). The current EU and US ESA-labelling
information recommends that ESAs not be used in AoC or
radiotherapy alone settings and that ESA therapy be initiated
in patients with a baseline haemoglobin p10 g dl1 (EU) or
o10 g dl1 (US).
Three other large study-level meta-analyses have also shown
that ESA use has a non-significant effect on survival in oncology
patients (Bohlius et al, 2006; Ross et al, 2006; Seidenfeld et al,
2006) (Table 2). In contrast, the recent meta-analysis by Bennett
et al (2008b) indicated that ESA-treated patients had significantly
increased mortality (Table 2). The discrepancy between this
finding and the findings from other meta-analyses, including this
study, may be because of differences in the data or studies
included for analysis (Bohlius et al, 2008). The present meta-
analysis included all 51 studies used in the Bennett et al (2008b)
study. However, a few studies included in the current analysis were
not included in the Bennett et al (2008b) meta-analysis (Bennett
et al, 2008b) or in a subsequent analysis performed by Bennett et al
(2008a) that was described in a letter to the editor. In addition, this
study included updated data (available either in recent publica-
tions or in unpublished study updates) not available to Bennett
et al (2008b).
Of further interest, two meta-analyses examining the effect of
ESA use on mortality in cancer patients were published after the
present meta-analysis was completed. One was a patient-level
meta-analysis carried out by the Cochrane EPO Individual Patient
Data (IPD) Meta-analysis Collaborative group (data were supplied
by Amgen, Centocor Ortho Biotech, Hoffman-La Roche and
several large investigator-initiated studies) (Bohlius et al, 2009)
and the other was a study-level meta-analysis carried out by the
Canadian Agency for Drugs and Technologies in Health (Tonelli
et al, 2009). In the Bohlius et al (2009) study, an analysis of
chemotherapy studies (38 studies with 10 441 patients) indicated
that the overall-survival HR was 1.04 (95% CI: 0.97–1.11) and the
HR for deaths on study was 1.10 (95% CI: 0.98–1.24) (Bohlius
et al, 2009). In all oncology settings (53 trials with 13 933 patients),
the HR for overall survival was 1.06 (95% CI: 1.00–1.12) and the
HR for on-study mortality was 1.17 (95% CI: 1.06–1.30). Though
the overall-survival HR for all oncology settings is nearly identical
Table 3 Sensitivity analysis of odds ratioa vs hazard ratiob for estimating mortality in chemotherapy studies with long-term follow-up
Number of
studies analysed Studies excluded
Summary
measure
Point
estimate 95% CI
20 None Study-level
OR
1.05 0.92–1.19
18 Engert, 2007; Strauss et al, 2008 Study-level
HR
1.04 0.95–1.14
16 Engert, 2007; Osterborg et al, 2005; Aapro et al, 2008a; Strauss et al, 2008 Study-level
OR
1.04 0.89–1.21
16 Engert, 2007; Osterborg et al, 2005; Aapro et al, 2008a; Strauss et al, 2008 Study-level
HR
1.04 0.94–1.15
16 Engert, 2007; Osterborg et al, 2005; Aapro et al, 2008a; Strauss et al, 2008 Patient-level
HR
1.03 0.95–1.11
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; OR¼ odds ratio. aORs were calculated for 20 studies with long-term follow-up data, for 16 studies where primary
data were available and for 18 studies with either a reported or calculated HR. The OR was based only on the number of deaths. bHRs were calculated for 16 studies where
primary data were available. Both study-level and patient-level analyses are provided.
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to the mortality OR estimated in the current meta-analysis, the HR
for on-study mortality reported by Bohlius et al (2009) for all
oncology settings indicated an increased risk of death with ESA
use. Differences between results reported by Bohlius et al (2009)
and results described here may reflect slight differences in the
methods and data used. The Bohlius et al (2009) study used a
straight intention-to-treat approach, whereas the current meta-
analysis used a modified intention-to-treat approach when data
were available for such an approach (only patients who received at
least one dose of study drug were analysed). In addition, although
60 controlled ESA studies
evaluated survival:
47 chemotherapy studies
9 AoC studies
4 radiotherapy only studies
26 controlled studies
evaluated
disease progression:
21 chemotherapy studies
1 AoC study
4 radiotherapy only studies
1 controlled study in AoC
has reported a trend for
increased disease progression
in the ESA group
Wright (2007)
2 controlled studies in patients
treated with radiotherapy only
have reported a statistically
significant increase in
disease progression in the
ESA group
Henke (2003)
Overgaard (2007)
2 controlled chemotherapy studies
have reported a trend for
increased disease progression
in the ESA group
Thomas (2008)
PREPARE press release (2007)
Study name
95% CI
Odds Lower Upper
ratio limit limit
Vansteenkiste 2002 0.58 0.30 1.11
Blohmer 2004 0.61 0.33 1.13
* Littlewood 2001 0.64 0.40 1.02
* Osterborg 2005 0.74 0.44 1.25
* Chang 2005 0.82 0.39 1.72
Leyland-Jones 2005 0.84 0.64 1.08
* Grote 2005 0.85 0.50 1.44
Engert 2007 0.86 0.33 2.24
Strauss 2008 0.87 0.32 2.33
Pirker 2008 0.87 0.52 1.46
* Milroy 2003 0.90 0.57 1.41
* Vadhan-Raj 2004 1.01 0.35 2.94
Thomas 2008 1.02 0.48 2.15
* Pronzato 2002 1.02 0.46 2.26
EPO-GBR-7 1.02 0.65 1.62
Moebus 2007 1.05 0.75 1.48
Machtay 2007 1.05 0.55 2.00
Aapro 2008a 1.07 0.82 1.40
Hedenus 2003 1.08 0.66 1.76
Wright 2007 1.08 0.30 3.95
* Witzig 2005 1.20 0.75 1.91
* Osterborg 1996 1.20 0.60 2.40
PREPARE 1.36 0.97 1.91
Henke 2003 1.56 1.01 2.39
Overgaard 2007 1.77 1.25 2.52
7.47 0.95 58.54
1 0.90 1.14
0.1 0.2 0.5 1 2 5 10
Favours control
Random effects model
* Wilkinson 2006
.01
Favours ESA
A
B
Figure 2 Effect of erythropoiesis-stimulating agent (ESA) use on disease progression. (A) Flow diagram of studies analysed. Of the 60 controlled ESA
studies that measured survival, 26 also measured a disease-progression outcome. AoC indicates anaemia of cancer. (B) Study-level meta-analysis of disease
progression-related endpoints in 26 controlled studies carried out in the settings of chemotherapy, AoC or radiotherapy only. This analysis included 9646
patients, with 4905 ESA-treated patients and 4721 control patients. An asterisk denotes studies where disease progression was evaluated only as part of
tumour assessment.
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the Bohlius et al (2009) meta-analysis used patient-level data, the
current meta-analysis only had access to published study-level
data for those trials or investigator-sponsored studies sponsored
by Hoffman-La Roche.
Similar to the current meta-analysis, the Tonelli et al (2009) meta-
analysis indicated a non-significant effect of ESA use on mortality
when 23 controlled trials (4273 patients) conducted in the
chemotherapy setting were examined (relative risk¼ 1.04; 95% CI:
0.86–1.26) (Tonelli et al, 2009). However, an analysis of 28 controlled
ESA trials (6525 patients) in all oncology settings indicated that ESA
use was associated with a higher relative risk for mortality (relative
risk¼ 1.15; 95% CI: 1.03–1.29) (Tonelli et al, 2009). Differences in
the results reported by Tonelli et al (2009) and by the current meta-
analysis may reflect differences in the studies analysed. Unlike the
current meta-analysis, the Tonelli et al (2009) meta-analysis included
publications written in a foreign language and studies conducted in a
Table 4 Risk of venous thromboembolism for patients receiving ESAs compared with patients not receiving ESAs: results from five meta-analysesa
Meta-analysis Number of trials Number of patients Statistic for VTE risk 95% Confidence interval
Present meta-analysis 44 13 196 1.48 OR 1.28–1.72
Bohlius et al, 2006 35 6769 1.67 RR 1.35–2.06
Seidenfeld et al, 2006 31 6412 1.68 RR 1.36–2.08
Ross et al, 2006 6 1463 1.41 OR 0.81–2.47
Bennett et al, 2008b 38 8172 1.57 RR 1.31–1.87
Abbreviations: ESA¼ erythropoiesis-stimulating agent; OR¼ odds ratio; RR¼ relative risk; VTE¼ venous-thromboembolic event. aResults from studies conducted in the
chemotherapy, radiotherapy and anaemia of cancer (AoC) settings are included.
Treatment type Study name
95% CI
Odds Lower Upper
ratio limit limit
AoC Smith 2003 0.49 0.08 3.16
Wright 2007 0.73 0.11 4.67
Smith 2008 1.58 0.62 4.04
Abels 1993 2.77 0.11 69.26
Gordon 2006 3.06 0.16 57.68
Charu 2007 4.63 0.26 81.36
Random effects model: AOC 1.36 0.68 2.74
Radiotherapy only Henke 2003 1.62 0.57 4.55
EPO-GBR-7 1.70 0.28 10.31
Machtay 2007 6.72 0.34 132.38
Random effects model: radiotherapy only 1.84 0.78 4.35
Bamias 2003 0.33 0.01 8.20
Blohmer 2004 0.34 0.03 3.30
Henry 1995 0.70 0.23 2.14
Case 1993 0.94 0.23 3.88
Grote 2005 0.97 0.52 1.81
Razzouk 2006 0.98 0.52 1.83
Kotasek 2003 1.03 0.40 2.68
Littlewood 2001 1.05 0.44 2.51
Leyland-Jones 2005 1.17 0.81 1.67
Chang 2005 1.27 0.74 2.17
Debus 2006 1.44 0.81 2.56
Vansteenkiste 2002 1.46 0.45 4.69
EPO-INT-1 1.47 0.15 14.38
Engert 2007 1.48 0.74 2.96
Taylor 2005 1.48 0.67 3.28
Witzig 2005 1.60 0.51 5.00
Pirker 2008 1.77 0.92 3.42
Moebus 2007 1.86 1.12 3.11
PREPARE 1.92 0.91 4.05
Hedenus 2003 2.00 0.73 5.46
Hedenus 2002 2.01 0.10 40.00
Aapro 2008a 2.41 1.22 4.76
Thatcher 1999 2.63 0.12 56.05
Thomas 2008 2.87 0.85 9.66
Throuvalas 2000 2.89 0.11 74.17
Osterborg 2005 3.07 0.12 75.91
Savonije 2005 3.53 0.43 29.11
Strauss 2008 3.63 0.14 91.98
Osterborg 1996 3.75 0.19 73.99
EPO-INT-3 4.03 0.49 32.94
Wilkinson 2006 5.32 0.66 42.54
Ten Bokkel 1998 5.34 0.29 97.55
Dammacco 2001 5.86 0.67 51.46
Vadhan-Raj 2004 8.18 0.92 72.91
Goss 2005 9.40 2.58 34.34
Random effects model: chemotherapy 1.48 1.27 1.72
Random effects model: overall 1.48 1.28 1.72
0.1 0.2 0.5 1 2 5 10
Favours controlFavours ESA
Chemotherapy
Figure 3 Study-level meta-analyses of venous-thromboembolic event (VTE) risk in 44 controlled studies carried out in the settings of chemotherapy,
anaemia of cancer (AoC) or radiotherapy only. This analysis included 13 196 patients with 7237 ESA-treated patients and 5959 control patients.
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peri-surgical setting. In addition, the Tonelli et al (2009) meta-
analysis did not include some key ESA trials (such as the BEST study
by Leyland-Jones et al, 2005), as anaemia due to chemotherapy was
not a study entry criterion.
Inconsistent results have also been reported across individual
ESA studies with regard to when an ESA-associated mortality
signal arises and in what tumour type it occurs. In chemotherapy
studies with high haemoglobin targets (X12 g dl1), decreases in
survival have been observed both during the treatment period
(e.g., in the first 4 months in the BEST study) (Leyland-Jones et al,
2005) and only after years of follow-up (ODAC, 2008; Hedenus
et al, 2003 and Amgen, data on file). For every study listed in the
US ESA-labelling information reporting an ESA-associated in-
crease in mortality and/or disease progression in a specific tumour
type (Amgen, 2009; Ortho, 2009), there is a study conducted in a
similar tumour type that did not report these safety signals. For
example, in cervical cancer, the GOG-0191 study (in 114 radio-
chemotherapy patients out of a planned 460) showed a non-
significant trend of increased disease progression and increased
mortality in ESA-treated patients at 3 years (Thomas et al, 2008).
In contrast, a similar study in cervical cancer (250 radio-
chemotherapy patients) showed no difference in the overall
survival between treatment arms after 4.8 years of follow-up
(Blohmer et al, 2004). In breast cancer, an unplanned analysis of
3-year interim data from the Preoperative Epirubicin Paclitaxel
Aranesp (PREPARE) study (733 chemotherapy patients) reported
increased mortality and increased disease progression in ESA-
treated patients (Amgen, 2007). However, final 5-year follow-up
results from another breast cancer study (643 chemotherapy
patients) showed no survival difference between treatment groups
(Moebus et al, 2007). Inconsistent safety signals have also been
observed in other cancer types, most notably haematological
malignancies (Osterborg et al, 1996, 2005; Hedenus et al, 2003).
The current EU and US ESA-labelling information contain no
restrictions on ESA use by tumour type (EMEA, 2008; eMC, 2008;
Amgen, 2009; Ortho, 2009).
The mechanism behind the ESA-associated increase in mortality
seen in some studies is unclear. One hypothesised mechanism is
that ESAs could stimulate disease progression by activating
erythropoietin receptors (EpoRs) that might be present on tumour
cells and/or tumour-associated vasculature. Several immunohis-
tochemistry studies using polyvalent rabbit anti-sera raised
against EpoR (i.e., polyclonal antibodies for EpoR) have reported
EpoR expression in some primary human tumours and endothelial
cells (reviewed in Osterborg et al, 2007; Sinclair et al, 2007).
Several studies have also reported that recombinant human
erythropoietin might have a proliferative or survival-promoting
effect on tumours (Takeshita et al, 2000; Westenfelder and
Baranowski, 2000; Acs et al, 2001; Lai et al, 2005; Feldman et al,
2006). However, the majority of pre-clinical studies have failed to
detect such effects when human tumour cell lines (in cell culture or
in rodent tumour models) are exposed to ESAs, even at supra-
pharmacological ESA concentrations (Osterborg et al, 2007;
Sinclair et al, 2007). Furthermore, several investigators have
independently demonstrated that commercially available EpoR
antibodies lack specificity and provide false-positive results with
immunohistochemistry (Elliott et al, 2006; Brown et al, 2007;
Sinclair et al, 2007; Laugsch et al, 2008). Recent studies have
also found that tumour cell lines and tumour biopsies do not
contain increased levels of EpoR mRNA transcripts compared
with normal tissue controls and that the EpoR gene is not
amplified in tumour cells (Sinclair et al, 2008). Overall, the
weight of preclinical evidence does not support a role for EpoR in
tumour growth. A recent workshop at the National Cancer
Institute (December 2007) concluded that conflicting and
confounding data exist regarding the expression and function of
EpoR protein on tumour cells and the association of EpoR
with disease progression. Additional research with more specific
EpoR-detection agents is needed to examine questions regarding
EpoR and disease progression.
Examining ESA use and disease progression is further
complicated by the fact that disease progression has not been a
primary or secondary endpoint in most oncology ESA studies. In
addition, great variation exists in the progression endpoints
measured (e.g., progression-free survival, tumour response,
local-regional relapse, and so on) and in the quality, consistency
and frequency of tumour assessments. Further, only those
chemotherapy studies targeting high haemoglobin levels
(X12 g dl1) have reported increased mortality with ESA use. If
an ESA-associated mortality risk is due to increased disease
progression, then this mortality risk would be expected to be
observed regardless of the target haemoglobin level. Additional
controlled studies are needed that prespecify disease progression
as a primary or secondary endpoint and that use consistent
methods with central review to collect and report the disease-
progression data.
Though an ESA-associated mortality signal in the chemotherapy
setting is only seen in studies targeting a high haemoglobin level
(X12 g dl1), not all such chemotherapy studies have reported this
signal (Pirker et al, 2008). Thus, the mechanism responsible for
ESA-associated mortality is unlikely to be solely related to the high
haemoglobin target. An exploratory analysis of six controlled
darbepoetin alfa chemotherapy trials indicated that patients who
responded poorly to ESA therapy (i.e., haemoglobin levels rose
very little or not at all; n¼ 1089) had a two-fold higher mortality
rate relative to patients who responded well to ESA therapy
(n¼ 385) (Amgen, data on file). Though poor ESA responders
appeared to drive the mortality signal in these chemotherapy
studies, reasons for the increased mortality were unclear. This
finding is notably confounded in that a poor response to ESA
therapy may be a marker for those patients with a poorer
prognosis (ODAC, 2008). The current ESA-labelling information
recommends halting ESAs in cancer patients who have no
haemoglobin response.
Poor ESA response as a driver for a mortality signal in studies
with high haemoglobin target has also been observed in the
nephrology setting. In both the Normal Hematocrit Cardiac
Trial (NHCT) (Besarab et al, 1998) and the Correction of
Hemoglobin in the Outcomes in Renal Insufficiency (CHOIR)
trial (Singh et al, 2006), patients randomised to arms with higher
haemoglobin targets had an elevated risk for a composite event
of cardiovascular hospitalisation and death. However, those
patients who achieved higher haemoglobin levels in both the
lower haemoglobin-target arms and the higher haemoglobin-target
arms had better outcomes. A re-analysis of data from the NHCT
higher haemoglobin-target arm showed that patients with
the lowest haemoglobin response had the highest mortality risk,
which was independent of other mortality predictors (Kilpatrick
et al, 2008).
The well-characterised risk of VTEs associated with ESA use has
been posed as a possible mechanism for the ESA-associated
mortality observed in some ESA studies. An increased VTE risk
with ESA use in the oncology setting is documented in the
scientific literature (Bohlius et al, 2006), in the US ESA-labelling
information (Amgen, 2007; Ortho, 2009), and is also supported by
the present meta-analysis. If poor ESA response drives the
mortality signal and the mechanism for increased mortality is
VTE incidence, the implication is that ESA exposure can increase
VTE risk by a mechanism unrelated to haemoglobin rise, as poor
responders show little or no increase in haemoglobin. An alternate
mechanism could be an effect of ESAs on Virchow’s triad of factors
that affect the pathogenesis of thrombosis, including hypercoagul-
ability, vessel-wall injury and venous stasis (Baron et al, 1998; Lee,
2002). Studies examining survival in ESA-treated cancer patients
treated with prophylactic low-molecular-weight heparin (to
decrease VTEs) (Geerts et al, 2004) would be enlightening.
Meta-analysis of ESA use and safety outcomes in oncology
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Studies are needed to further explore the effect of ESA use on
survival and disease progression, to definitively determine what
can drive ESA-associated mortality, and to evaluate factors that
may identify patients most at risk for increased mortality with ESA
use. Important information will be provided from ongoing clinical
trials such as the PREPARE trial and the EPO-ANE-3010 trial,
which is an open-label, randomised and controlled trial in
metastatic breast cancer patients measuring progression-free
survival (primary endpoint) and overall survival (secondary
endpoint) (Centocor Ortho Biotech, data on file). A large,
placebo-controlled, non-inferiority study in non-small-cell lung
cancer has been proposed in which randomisation will be stratified
by prognostic factors (study 20070782; Amgen, data on file) and
overall survival (primary endpoint) and progression-free survival
(secondary endpoint) will be examined. Results from these and
additional trials and from inclusive meta-analyses will provide
important evidence to inform evidence-based decision making.
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